Given the substantial evidence supporting BDNF as a biomarker for treatment response in MDD for pharmacologic agents and the limited but positive evidence in perinatal depression, targeted research is needed to evaluate its translational utility in monitoring treatment response in perinatal depression more broadly. The gene discussed is BDNF; the disease is perinatal asphyxia.